Human Trials

Ipsen announces positive results from ENGAGE study of Dysport combo with GSC in adults with upper and lower limb spastic hemiparesis

Ipsen announced first results from the ENGAGE study which reports that simultaneous treatment with Dysport of both upper and lower limb spasticity in adult patients along with a Guided Self-rehabilitation Contract (GSC) – a personalized diary-based rehabilitation program – improved patients’ voluntary movement as measured by a composite active range of motion (CXA) outcome.

Clovis Oncology acquires rights to FAP-targeted radiopharmaceutical programme from 3B Pharmaceuticals

Clovis Oncology has entered into a global licensing and collaboration agreement with 3B Pharmaceuticals GmbH (3BP), a private German biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for oncology indications with a high unmet medical need.

Cerevel’s tavapadon meets primary endpoint in phase 2 trial in Parkinson’s disease

Cerevel Therapeutics said that a phase 2 trial assessing orally-administered tavapadon (formerly PF-06649751) in patients with early-stage Parkinson’s disease has met its primary endpoint.

Graybug Vision initiates clinical trial in macular edema secondary to diabetic macular edema or retinal vein occlusion

Graybug Vision, a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and primary open angle glaucoma (POAG), announced the initiation of its Phase 2a study with GB-102 in patients with macular edema (ME) secondary to DME or RVO.

Novartis’ Cosentyx meets primary endpoint at Week 16 in PREVENT trial

Novartis said that the phase 3 trial of its psoriasis drug Cosentyx (secukinumab), called PREVENT, in patients with non-radiographic axial spondyloarthritis (nr-axSpA), has met its primary endpoint at Week 16.

Concert Pharmaceuticals completes enrollment in second open label trial of CTP-543 in alopecia areata

Concert Pharmaceuticals announced that it has completed patient enrollment of an open label clinical trial to evaluate once-daily 24 mg compared to twice-daily 12 mg oral dosing of CTP-543 in patients with alopecia areata.

Poxel initiates phase 1b multiple ascending dose trial for NASH drug candidate

POXEL, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced the initiation of a Phase 1b double-blind, randomized, placebo-controlled study in healthy subjects to evaluate the safety, tolerability and pharmacokinetics (PK) as well as support dose selection for a pivotal study of PXL065.

Alnylam initiates APOLLO-B phase 3 study of patisiran for treatment of transthyretin amyloidosis with cardiomyopathy

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company has initiated APOLLO-B, a global Phase 3 placebo-controlled clinical trial of patisiran, an intravenously administered RNAi therapeutic, for the treatment of transthyretin amyloidosis (ATTR amyloidosis) with cardiomyopathy.

Arrowhead presents initial top-line clinical data and preclinical data on RNAi candidates ARO-APOC3 and ARO-ANG3

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented initial top-line clinical data at The Global Summit on Cardiology and Heart Diseases, being held in Dubai, UAE